Hence the suggestion about using IFNLs as an antiviral in COVID-19 patients or in subjects at high risk of infection, currently in clinical trials with peg-IFN L1, would not be supported (Prokunina-Olsson et al., 2020). Here, IFNL1 is linked to COVID-19.